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Abstract 
Being able to predict, with accuracy, the disease progression of patients with a given 
disease is extremely useful from the perspectives of clinicians, patients, and clinical trial 
investigators. We introduce a novel method of reducing the expected prediction error when using 
linear models, given approximate monotonicity of the response; we refer to this method as 
utilizing an “anchor.” We justify this method mathematically, and then show how to improve 
predictions arising from standard ordinary least squares (OLS) models when modelling disease 
progression in a population of patients with amyotrophic lateral sclerosis (ALS).  
We go on to show that using an anchor can be used in conjunction with more complex 
modelling schemes to further improve the predictions of ALS patients; an anchor improves both 
Bayesian hierarchical linear models and Bayesian mixture models. Furthermore, we explore 
potential covariates that may be included in the models to improve predictions, but find that only 
time of disease onset results in improved model performance.  
We also explore how well these models work in a clinical setting, rather than in a clinical 
trial. We first demonstrate the feasibility of automatically extracting patients’ data, pertaining to 
survival and disease progression, from the electronic medical record, as well as showing that our 
disease progression model is feasible for clinical patients. We then compare survival rates 
between the two populations and determine that, even after adjusting for several important 
covariates, there is a large difference between survival in the clinic setting and survival in ALS 
clinical trials. We assert that the two patient groups’ differences in disease progression and 
survival highlight the needs to understand better disease variability in the clinical setting and to 
refine the inclusion criteria in ALS trials.  
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We determine an anchor can be used to improve predictive models in ALS disease 
progression, for both simple independent OLS regressions and for far more complicated 
Bayesian hierarchical linear models. We conclude that using a Bayesian hierarchical linear 
model with an anchor is useful in both a clinical trial population of ALS patients as well as a 
dissimilar population seen in the Midwestern academic medical center ALS clinic. 
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Introduction 
 Predictive modelling, while always an important aspect of statistics, recently has enjoyed 
a meteoric surge in popularity and attention due to the advent of big data and improved machine 
learning techniques. One interesting result of this is the rise of competitive data prediction 
challenges, such as the well-known Netflix challenge (1) which tasked teams with the goal of 
trying to produce an algorithm to determine users’ ratings of given movies. Data prediction 
challenges occurred in all sorts of industrial and academic fields, including medicine (2). One 
challenge in particular, the ALS Stratification Challenge, tasked teams with trying to build 
predictive models that could predict the disease progression of patients with amyotrophic lateral 
sclerosis (ALS), also known as Lou Gehrig’s disease (3).  
ALS is a rarely occurring neurodegenerative disease that causes full-body paralysis and 
eventually death in those afflicted by it. Progression of the ALS is determined by the ALS 
Functional Rating Scale (ALSFRS) or the ALSFRS-Revised (ALSFRS-R), which is ten or 
twelve clinician-administered questions resulting in a score between zero and 40 (ALSFRS) or 
48 (ALSFRS-R). A higher score corresponds to more function, and as the disease progresses 
(causing function to deteriorate) the ALSFRS score decreases, with scores under 24 representing 
serious loss of function.  
Because ALS has large amounts of between-subject variability and is rarely occurring, 
ALS is a very difficult disease to study; trials require very large sample sizes to be adequately 
powered to accommodate the variability, which is difficult due to ALS’s rarity. To assist in this, 
the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database was created (4). 
PRO-ACT consists of data from dozens of ALS clinical trials (all individually negative, meaning 
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no significant improvement was found when using the treatment), and contains ALSFRS, lab 
values, survival information, and more for thousands of ALS patients.  
Data in PRO-ACT was used by participants in the ALS Stratification challenge to both 
train and validate models. The winners of this challenge used random forest models (3), which 
are nonparametric and consequently are difficult to explain and interpret. This was the second 
large-scale crowd-sourced ALS data prediction challenge where the winners all utilized popular 
nonparametric approaches: the first being the DREAM Phil Bowen ALS Prediction challenge by 
Prize4life (5). The result of both of these challenges was that all top-performing teams used 
nonparametric models, such as Bayesian trees and random forests. Because of the linearity of the 
ALSFRS and ALSFSR-R, a parametric predictive linear model could also be a good candidate 
for measuring ALS progression. A linear model would be especially useful because of its easily-
interpreted parameters.   
There would be many potential advantages for having a successful explainable predictive 
model for ALS progression for not only ALS patients and their doctors, but also for those who 
are interested in developing new ALS therapeutics (5). One particular hurdle to developing such 
a model comes from the fact that many patients in the challenge had very few measurements: 
some patients had as little as one single data-point with which to construct a prediction. Because 
of this, even though the disease progression was fairly linear over time (6, 7), standard linear 
modelling techniques encountered difficulties; fitting a linear model through one or even two 
points allowed for too much variability in the predictions. This led us to develop a new 
methodology to reduce the variability of predictions, which we refer to as using an “anchor.” The 
anchor is an additional data point used in the regression that is created by intelligently assuming 
a particular value for the response when the process being modelled first began. 
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In chapter one of this dissertation we describe the mathematics which prove that 
including an anchor in the context of ordinary least squares (OLS) regression will reduce the 
variability of the resulting predictions. This comes at the cost of possibly increasing the bias of 
these predictions. We then go on to show how this method can be used in modelling disease 
progression of ALS patients by modelling each patient’s disease progression independently. 
Since we have the actual disease progressions of each patient, we can easily compare the model 
that uses an anchor to one that does not, and see that the anchor results in dramatically improved 
predictive performance. Additionally, we see that the anchor allows us to make predictions much 
sooner and with less data than the traditional OLS model can.  
In chapter two, we consider a more rigorous approach of modelling the disease 
progression of ALS patients. We formally test various linear models via cross-validation, 
ultimately deciding on a Bayesian hierarchical linear model using an anchor as the best model. 
We conduct a cross-validation to assess the benefit of including various covariates in said model. 
We conclude that the only covariate that improves prediction for a patient’s disease progression 
is knowledge of when the patients first began having symptoms of ALS.  
Finally, in chapter three we discuss the feasibility of creating disease progression and 
survival data models using ALS patient data that is automatically extracted from the electronic 
medical record (EMR). We look at the differences in disease progression and survival rates 
between ALS clinic patients and clinical trial subjects. We conclude that there is an urgent need 
to better understand disease variability in ALS patients, as well as a need to refine the inclusion 
criteria in ALS clinical trials.  
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Chapter 1: Using an Anchor to Improve Linear Predictions 
1.0 Abstract 
Linear models are some of the most straightforward and commonly used modelling 
approaches. Consider modelling approximately monotonic response data arising from a time-
related process. If one has knowledge as to when the process began or ended, then one may be 
able to leverage additional assumed data to reduce prediction error. This assumed data, referred 
to as the “anchor,” are treated as an additional data-point generated at either the beginning or end 
of the process. The response value of the anchor is equal to an intelligently selected value of the 
response (such as the upper bound, lower bound, or 99
th
 percentile of the response, as 
appropriate). The anchor reduces the variance of prediction at the cost of a possible increase in 
prediction bias, resulting in a potentially reduced overall mean-square prediction error. This can 
be extremely effective when few individual data points are available, allowing one to make 
linear predictions using as little as a single observed data point. We develop the mathematics 
showing the conditions under which an anchor can improve predictions, and demonstrate using 
this approach to reduce prediction error when modelling the disease progression of patients with 
amyotrophic lateral sclerosis.  
1.1 Introduction 
Prediction always has been an important part of statistical modeling. With the advent of 
big data and the rise of machine learning, one may think that researchers have moved beyond 
prediction via simple linear models. This is not the case, however, especially in the field of 
medical research; a quick search of PubMed from January 2016 through July 2017 results in over 
1000 publications that utilize linear (but not generalized linear) models. This is because linear 
models are usually one of the first attempted approaches when analyzing new data, and 
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surprisingly often, they are sufficient. Linear models are simple to calculate, requiring tiny 
amounts of computing power compared to some of the more complex machine-learning 
algorithms (such as neural networks). Most importantly, linear models are very straightforward 
to interpret and explain; a direct contrast to the more sophisticated “black-box” methods that are 
dependent on large datasets. The ability to interpret and understand statistical models, or model 
intelligibility, especially is important in the field of healthcare (1). 
Yet linear models have their failings, especially when modelling a bounded response. 
Consider attempting to model the disease progression over time of a patient with amyotrophic 
lateral sclerosis (ALS), also known as Lou Gehrig’s disease. This is measured by the instrument 
known as the ALS Functional Rating Scale – Revised, or ALSFRS-R (2). The ALSFRS-R is 
always an integer between zero and 48, with 48 representing no spread of the disease and zero 
being the theoretical maximal spread of the disease. The progression of the ALSFRS-R tends to 
be very linear (3, 4), but because of its bounded nature, simple linear models have the inherent 
structural defect of creating predictions that violate the lower and upper bounds. Many 
adjustments to this problem exist; examples include truncating the prediction to 48 if the 
prediction is too large (0 if too small) (5) or performing a logistic transform on the data (6).  
If the goal is prediction (e.g., the patient’s ALSFSR-R at one year), these adjustments may not 
perform well when small amounts of observed data exist. The small number of data  
points can result in the variance of the prediction being very large, producing a large mean-
squared prediction error (MSPE). Recall the MSPE is equivalent to the sum of the variance and 
squared bias of the prediction.  
In this paper we consider a simple method to reduce the variability of linear predictions at 
the cost of potentially increasing the predictive bias. Biased linear regression itself is not new 
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(ridge regression (7) is one well-known example), but we do this in a unique way by exploiting 
our knowledge of when the process we are modeling (e.g. the patient’s disease progression) first 
began.  
Tracking the date when a patient first began noticing symptoms of ALS (their disease 
onset time) is common practice in ALS clinics and trials. From a modelling perspective, one 
could use this information in a variety of ways; the most obvious way is using it as a covariate in 
the model. Using a different approach, if we were to assume their ALSFRS-R score at roughly 
the time of their disease onset, what might their ALSFRS-R be? One could argue that the patient 
has had minimal, if any, disease progression at time of disease onset. It seems reasonable that 
one could assume their ALSFRS-R to be 48 (meaning the minimum possible disease 
progression) at this time. We could then create a new observation with ALSFRS-R score of 48 at 
the time of disease onset, and include that as one of the observations (data points) used to build 
our linear model.  
In this paper we consider using knowledge of when a process starts to create an assumed 
data point that can be used to reduce variability of linear model predictions. We found no 
previous literature on this technique in our literature search. First we show how the inclusion of 
this point mathematically reduces the variance component of the MSPE under the assumptions of 
ordinary least-squares (OLS) linear regression. Then we calculate the bias component it brings to 
the MSPE; and we deduce the condition under which this approach can reduce the MSPE in 
predication combined variance and bias. Afterwards we give an example using this approach in 
the context of modeling ALS disease progression, showing how it improves the MSPE when 
compared to a linear model lacking the extra data point. We show how it is also superior to a 
logistic transform approach. We stress that this method is a simple to understand, easy to 
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perform, and inexpensive to implement approach. It is our hope that this approach may be used 
by pragmatic researchers to improve their linear predictions and estimations at very little 
additional cost. 
1.2 Theoretical Results for Simple Linear Regression 
Here we develop the theoretical results that justify the creation and use of an extra 
assumed data point to improve modelling. We shall refer to this data point as the “anchor.” 
Consider 𝑛 − 1 ordered pairs {(𝑥𝑖, 𝑦𝑖)}, 𝑖 ∈ 1 … 𝑛 − 1, where 𝑦𝑖 is some response corresponding 
to 𝑥𝑖. As per ordinary linear regression (8), assume that 𝑥𝑖 and 𝑦𝑖 have a linear relationship, 
meaning that for some constants 𝛽0 and 𝛽1, 𝑦𝑖 = 𝛽0 + 𝛽1𝑥𝑖 + 𝜖𝑖, with independent error terms 
𝜖𝑖~𝑁(0, 𝜎
2).  Furthermore, assume an additional observation referred to as the “anchor” given 
by (𝑥𝑛, 𝑦𝑛), where 𝑦𝑛 is some fixed constant in ℝ.  
Consider the problem of predicting a new value 𝑦0 corresponding to a given 𝑥0, that 
typically is obtained by using the OLS estimates for 𝛽0 and 𝛽1, denoted as 𝑎 and 𝑏. Denote the 
resultant prediction for 𝑦0 that uses the first 𝑛 − 1 coordinate pairs by ?̂?0
(𝑛−1) = 𝑎(𝑛−1) +
𝑏(𝑛−1)𝑥0, and the prediction that also includes the anchor by ?̂?0
(𝑛)
= 𝑎(𝑛) + 𝑏(𝑛)𝑥0. Denote the 
errors between our prediction and the truth to be 𝑒0
(𝑛−1)




= 𝑦0 − ?̂?0
(𝑛)
. 
Recall that the variance of  𝑒0
(𝑛−1)
 (that was built from 𝑛 − 1 ordered pairs of data in standard 
OLS regression) is equivalent to:  
𝑣𝑎𝑟(𝑒0
(𝑛−1)) = 𝑣𝑎𝑟(𝑦0 − ?̂?0




















) represents the variance of the prediction error 
obtained from utilizing all 𝑛 data points (meaning we include the anchor).  
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), meaning any choice of anchor will 
decrease the variance component of the MSPE. We then derive an upper bound for the bias of 
the anchor such that the MSPE will decrease; in other words, how far away from the “true” line 
can the anchor be before it makes the MSPE worse.  
Without loss of generality, we will assume the following for the observed data: 






= 0 and 
√∑ 𝑥𝑖
2𝑛−1
𝑖=1 = 1. Then the following hold: 





























Any collection of (𝑥𝑖, 𝑦𝑖) can be linearly transformed in the 𝑥-coordinate by subtracting the 
mean of the 𝑥’s and dividing by the Euclidean norm √|| < 𝑥1, … , 𝑥𝑛−1 > || to achieve this. It is 
interesting to point out that this transformation has no impact on the OLS estimators for 𝜎2. 





Proof: Let 𝑎, 𝑏 be the OLS estimated intercept and slope through the points (𝑥1, 𝑦1) … (𝑥𝑛, 𝑦𝑛). 








) = 𝑣𝑎𝑟(𝑦0 − ?̂?0
(𝑛)
) = 𝑣𝑎𝑟(𝑦0) + 𝑣𝑎𝑟(𝑎 + 𝑏𝑥0). Utilizing our assumptions on 




) holds if and only if: 
𝑣𝑎𝑟(𝑦0) + 𝑣𝑎𝑟(𝑎 + 𝑏𝑥0) ≤ 𝑣𝑎𝑟(𝑒0
(𝑛−1)) 
















Which simplifies as follows: 
𝜎2 + 𝑣𝑎𝑟(𝑎) + 𝑥0













We next consider the individual terms 𝑣𝑎𝑟(𝑎), 𝑣𝑎𝑟(𝑏),  and 𝑐𝑜𝑣(𝑎, 𝑏). For convenience 𝑆𝑆𝑋 
denotes 𝑆𝑆𝑋(𝑛) and ?̅? denotes ?̅?(𝑛). 
Part 1: variance of slope 












Recall 𝑣𝑎𝑟(𝑦𝑖) = 𝜎
















Utilizing the assumption that ∑ (𝑥𝑖
2)𝑛−1𝑖=1 = 1 and that ∑ (𝑥𝑖)
𝑛−1




(1 + (𝑛 − 1)?̅?2). 
Or equivalently 






(𝑛𝑥𝑛2 + 𝑛 − 𝑥𝑛2)2
.   
 
Part 2: variance of intercept 
Since 𝑣𝑎𝑟(𝑦𝑛) = 0: 



















































2 + 𝑛 − 𝑥𝑛
2)2
. 
Part 3: covariance of intercept and slope 
Consider 𝑐𝑜𝑣(𝑎, 𝑏). We use the property that 𝑐𝑜𝑣(∑ 𝑐𝑖𝑦𝑖 , ∑ 𝑑𝑖𝑦𝑖) = 𝜎
2∑(𝑐𝑖𝑑𝑖) and the 
fact that any covariance or variance term involving 𝑦𝑛 is 0, since 𝑦𝑛 is a constant.  




































































(1 + (𝑛 − 1)?̅?2) ) 
Or equivalently 
𝑐𝑜𝑣(𝑎, 𝑏) = −𝜎2
𝑥𝑛(𝑛𝑥𝑛
2 + 2𝑛 − 𝑥𝑛
2 − 1)
(𝑛𝑥𝑛2 + 𝑛 − 𝑥𝑛2)2
. 




(𝑛−1)) is equivalent to the following: 
𝑣𝑎𝑟(𝑎) + 𝑥0












(𝑛𝑥𝑛2 + 𝑛 − 𝑥𝑛2)2
) + 𝑥0 (2
𝑥𝑛(𝑛𝑥𝑛
2 + 2𝑛 − 𝑥𝑛
2 − 1)








2 + 𝑛 − 𝑥𝑛
4 − 𝑥𝑛
2 − 1
(𝑛𝑥𝑛2 + 𝑛 − 𝑥𝑛2)2
). 
The right hand side of the inequality is quadratic in 𝑥0
2 with form 𝑔(𝑥0) = 𝐴𝑥0
2 + 𝐵𝑥0 + 𝐶. Note 




2 + 2𝑛 − 𝑥𝑛
2 − 1)




2 + 2𝑛 − 𝑥𝑛
2 − 1)




2 + 2𝑛 − 𝑥𝑛
2 − 1)
(𝑛 − 1)(𝑛𝑥𝑛2 + 𝑛 − 𝑥𝑛2)2
. 
Since 𝐴 > 0 for 𝑛 > 2, then 𝑔(𝑥0) is an upward-facing parabola. Also, the discriminant, given 
by 𝐵2 − 4𝐴𝐶, is equal to zero: 
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𝐵2 − 4𝐴𝐶 =
4𝑥𝑛
2(𝑛𝑥𝑛
2 + 2𝑛 − 𝑥𝑛
2 − 1)2




2 + 2𝑛 − 𝑥𝑛
2 − 1)
(𝑛𝑥𝑛2 + 𝑛 − 𝑥𝑛2)2
(𝑛𝑥𝑛
2 + 2𝑛 − 𝑥𝑛
2 − 1)





2 + 2𝑛 − 𝑥𝑛
2 − 1)2




2 + 2𝑛 − 𝑥𝑛
2 − 1)2
(𝑛𝑥𝑛2 + 𝑛 − 𝑥𝑛2)4
 
= 0, 
meaning there is exactly one root in 𝑔(𝑥0). Therefore, it must be true that 𝑔(𝑥0) ≥ 0 and  
𝑣𝑎𝑟(?̂?0
(𝑛)) ≤ 𝑣𝑎𝑟(?̂?0
(𝑛−1)) as desired. 
∎ 
Thus we see that any choice of anchor necessarily will result in a reduction in the 
variance of the prediction of 𝑦0, that is equivalent to a reduction of the variance component of 
the MSPE. However, we still need to consider the bias. Recall that the typical OLS estimators for 
slope and intercept are unbiased. We next consider how much bias can be introduced before 
utilizing the anchor that no longer benefits the MSPE of our predictions. It will be shown that 
any choice of an anchor (𝑥𝑛, 𝑦𝑛) such that 𝑦𝑛 ≠ 𝛽0 + 𝛽1𝑥𝑛 will introduce bias to the model. Note 
that the bias is a direct function of 𝛽0 and 𝛽1, that rarely are known in practice. Again, let ?̅? 
denote ?̅?(𝑛) and 𝑆𝑆𝑋 denote 𝑆𝑆𝑋(𝑛) = ∑ 𝑥𝑖
2𝑛
𝑖=1 . 
Theorem 2: Using anchor point (𝑥𝑛, 𝑦𝑛) results in biasing the slope by   
𝐸(𝑏 − 𝛽1) =




Proof: Recall 𝑦𝑖 = 𝛽0 + 𝛽1𝑥𝑖 + 𝜖𝑖 and that the OLS estimate for 𝛽1, denoted by 𝑏, is given by  
𝑏 =
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We first derive 𝐸(𝑏): 






















































Note that the OLS estimate for 𝛽0 when not using the anchor point is given by  
𝑎(𝑛−1) = ?̅?(𝑛−1) − 𝑏(𝑛−1)?̅?(𝑛−1) = ?̅?(𝑛−1) since ?̅?(𝑛−1) = 0. Similarly, 𝑏(𝑛−1) = ∑ {𝑥𝑖𝑦𝑖  }
𝑛−1
𝑖=1 . 
Since these are the unbiased OLS estimators for 𝛽0 and 𝛽1 when ignoring the anchor point, then 
it must be that 𝐸(?̅?(𝑛−1)) = 𝛽0 and 𝐸(∑ {𝑥𝑖𝑦𝑖 }
𝑛−1





































(𝛽1 + 𝑥𝑛 (
𝑛 − 1
𝑛
) (𝑦𝑛 − 𝛽0)). 
Or equivalently 
𝐸(𝑏) =
(𝑛 − 1)𝑥𝑛(𝑦𝑛 − 𝛽0) + 𝛽1𝑛
𝑛𝑆𝑆𝑋
, 
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that means the bias 𝑏 is given by 
𝐸(𝑏 − 𝛽1) =




Theorem 3: Using anchor point (𝑥𝑛, 𝑦𝑛) results in biasing the intercept by   
𝐸(𝑎 − 𝛽0) =
𝛽0(𝑛 − 1)(𝑥𝑛




Proof: Recall that the OLS estimate for 𝛽0, denoted by 𝑎, is given by  




We first calculate 𝐸(𝑎): 





















((𝑛 − 1)𝑥𝑛(𝑦𝑛 − 𝛽0) + 𝛽1𝑛), 
that can be reduced to  
𝐸(𝑎) =
𝛽0(𝑛 − 1)(𝑥𝑛
2 + 1) − 𝛽1𝑥𝑛 + 𝑦𝑛
𝑛𝑆𝑆𝑋
. 
Therefore the bias of the intercept is  
𝐸(𝑎 − 𝛽0) =
𝛽0(𝑛 − 1)(𝑥𝑛




Corollary: The overall bias induced by using anchor point (𝑥𝑛, 𝑦𝑛) is given by 
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𝐸(?̂?0 − 𝑦0) = 𝐸(𝑎 + 𝑏𝑥0 − 𝛽0 − 𝛽1𝑥0) 
=
𝛽0(𝑛 − 1)(𝑥𝑛
2 + 1) − 𝛽1𝑥𝑛 + 𝑦𝑛
𝑛𝑆𝑆𝑋
− 𝛽0 + 𝑥0 {
(𝑛 − 1)𝑥𝑛(𝑦𝑛 − 𝛽0) + 𝛽1𝑛
𝑛𝑆𝑆𝑋
− 𝛽1}. 
Corollary: The anchor point introduces no bias, meaning ?̂?0
(𝑛)
 is unbiased, only if 𝑦𝑛 = 𝛽0 +
𝛽1𝑥𝑛. 


















(𝛽1 − 𝛽0𝑥𝑛 (
𝑛 − 1
𝑛
) + 𝑥𝑛 (
𝑛 − 1
𝑛















) = 𝛽1 (
𝑆𝑆𝑋
𝑆𝑆𝑋
) = 𝛽1. 















Using the derivation above for 𝐸(𝑏) = 𝛽1. This then simplifies to be 
𝐸(𝑎) = 𝛽0, 
meaning 𝑎, 𝑏 are unbiased and therefore 𝐸(?̂?0
(𝑛)
) = 𝐸(𝑎 + 𝑏𝑥0) = 𝛽0 + 𝛽1𝑥0 = 𝑦0. 
∎ 
Theorem 4: Utilizing anchor point (𝑥𝑛, 𝑦𝑛) reduces the overall MSPE when the following 
inequality holds: 




2 + 1) − 𝛽1𝑥𝑛 + 𝑦𝑛
𝑛𝑆𝑆𝑋
− 𝛽0 + 𝑥0 {










2 + 2𝑛 − 𝑥𝑛
2 − 1)
𝑛2𝑆𝑆𝑋2
) + 𝑥0 (
2𝑥𝑛(𝑛𝑥𝑛










Proof: Consider the following inequality 
𝑀𝑆𝑃𝐸(𝑛) ≤ 𝑀𝑆𝐸(𝑛−1). 















) = 0, and that 𝑣𝑎𝑟(𝑒0
(𝑛−1)









), were derived in Theorem 2 and Theorem 3, and substituting 
them in to this inequality results in the formula given in the statement of Theorem 4. 
∎ 
Thus, we see that any choice of anchor point will reduce the variance of prediction, but 
will increase the bias of the prediction depending on how far away the anchor point is from the 
“true” regression line. Therefore, using an anchor may be beneficial or not, depending on how 
much bias is added. 
The bound calculated in Theorem 4 potentially could be used as a decision rule for 
determining if using an anchor is beneficial or not. Unfortunately, one needs to know the true 
values of 𝛽0 and 𝛽1 in order to use Theorem 4’s result. In practice, one tends not to know the true 
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regression parameters, although with sufficiently informed prior knowledge, precise estimates 
may exist. Thus, when deciding whether to use an anchor or not, we suggest comparing the 
anchor model to a standard model using a cross-validation approach. We show an example of 
this in the results section. 
Before moving to the application section, we note that many of the ideas in this paper 
have Bayesian connections. For example, consider performing a Bayesian analysis of classical 
regression. When using the standard noninformative prior distribution, the posterior mean 
estimates for the slope and intercept terms (and their standard errors) are equivalent to those 
obtained under frequentist OLS (9). It follows that Theorems 1-4 still hold under the Bayesian 
paradigm, meaning that an anchor can be used to reduce the variance of posterior predictions. 
1.3 Application to ALS Prediction  
We next consider using an anchor to improve linear models that pertain to predicting 
disease progression in patients with ALS. Note that the theory developed in part (2) applies to a 
single OLS regression (prediction for the individual). The following example expands on this by 
showing how using an anchor can improve the average prediction error across several OLS 
regressions (prediction for each of several individuals). 
Our data come from the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) 
database (10). In 2011, Prize4Life, in collaboration with the Northeast ALS Consortium, and 
with funding from the ALS Therapy Alliance, formed the PRO-ACT Consortium. The data 
available in the PRO-ACT Database have been volunteered by PRO-ACT Consortium members 
(https://nctu.partners.org/PRO-ACT/).   
Recall ALS disease progression is tracked by the ALSFRS-R, our outcome variable, that 
is an integer value between zero and 48, where 48 represents the minimal amount of disease 
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progression and zero represents the maximal progression. For each patient, we model the 
ALSFRS-R versus time (in days). Specifically, time is measured in days from trial baseline, 
meaning 𝑥 = 0 corresponds to the beginning of the trial and 𝑥 = 365 corresponds to the 365th 
day after the trial began. On this scale, a patient’s disease onset time is typically negative, as it 
happened before the trial began. We required patients to have the following: (1) at least two 
recorded ALSFRS-R scores before 3 months, for model building purposes; (2) non-missing 
value for time of disease onset; (3) at least one year between the baseline and last ALSFRS-R 
score for MSPE-validation purposes. This resulted in 1,606 patients, with an average ± standard 
error (SE) of 12 ± 4.54 time-points per patient (and 3 ± 0.96 visits in the first three months). 
Note that we are now considering longitudinal data. Volumes have been written on 
modelling strategies for data such as this; hierarchical models, mixed models, time series, and 
machine learning algorithms all would make good candidates for the modeling of this. However, 
to demonstrate how using the anchor-point improves OLS regression, we simply will model each 
patient independently with: (1) a standard OLS regression model and (2) with an OLS regression 
model using an anchor. Note that the ALSFRS-R follows a fairly linear decline, although each 
patient exhibits wide variation in their patient-specific progression rates, justifying using linear 
models (Figure 1.1). The assumed data point, or anchor, used in the anchor model comes from 
assuming minimal disease progression at the time of disease onset. In other words, each patient’s 
data is augmented with the additional data point given by the ordered pair (𝑥𝑜𝑛𝑠𝑒𝑡, 48), since 48 
is the ALSFRS-R corresponding to minimal progression.  
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Figure 1.1: For nine randomly selected subjects, we plotted their ALSFRS-R versus time. The 
leftmost black square is the anchor, the rightmost square is the true value 𝑌𝑘, and the gray 
triangles are observed scores. The dashed black lines denote days 0 and 92 of the trial, meaning 
observations between the two dashed lines were used for model fitting. 
We will compare the standard model versus the anchor model by comparing their ability 
to predict each patient 𝑘′𝑠 first ALSFRS-R score after 365 days (1 year), observed at time 𝑥𝑘,0, 
using only ALSFRS-R scores measured before 92 days (3 months). Specifically for both models 
we calculate  
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√𝑀𝑆𝑃𝐸 = √





where ?̂?𝑘 is the predicted ALSFRS-R score for patient 𝑘 at time 𝑥𝑘,0 and 𝑌𝑘 is the true ALSFRS-
R score at time 𝑥𝑘,0. Because we know the ALSFRS-R is bounded between 0 and 48, any model 
prediction that falls outside these bounds will be truncated to the closest boundary value before 
evaluating the MSPE. To assist in visualizing this data, Figure 1.1 shows the progression of the 
ALSFRS-R versus time for nine subjects (simple random sample without replacement). 
The anchor model results in slightly more biased predictions compared to those of the standard 
model, as expected. However, as demonstrated in the methods section, the variance of these 
errors is much smaller for the anchor model (Figure 1.2). The resulting root MSPE of the anchor 
model is 7.8 while the standard model’s MSPE is 13.0; we observe a large drop in prediction 
error when including the anchor.  
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Figure 1.2: The raw prediction error for the anchor and standard models. The models’ mean error 
as measured by ?̂?𝑘 − 𝑌𝑘 was 3.1 and 2.1 respectively, with standard deviations of 7.1 and 12.7. 
It can be shown that for some patients, the prediction from the standard model is closer to 
the truth than the prediction from the anchor model. Perhaps we should only use the anchor 
model when the increase in bias is negligible. We could explore this by taking the difference 
between the prediction from the anchor model ?̂?(𝑎) and the standard model ?̂?(𝑠); if this 
difference is sufficiently small in magnitude then the increase in bias from using the anchor 









   𝑖𝑓 |𝑇𝑘| ≤ Γ
?̂?𝑘
(𝑠)
    𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
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for some constant Γ. Figure 1.3 shows how this changes the MSPE for various values of Γ, as 
well the result from changing the rule to be ?̂?𝑘 = ?̂?𝑘
(𝑎)
   𝑖𝑓 |𝑇𝑘| ≥ Γ instead (meaning choose the 
anchor model if the difference in the model predictions is large). From Figure 1.3 we see that 
naively using the anchor model for all patients outperforms any of the Γ and 𝑇𝑘 decision-rule 
hybrids for this dataset. 
 
Figure 1.3: Shows the resulting MSPE for various cutoffs of Γ. Note that since the MSPE is 
bounded below by the anchor model (√𝑀𝑆𝑃𝐸 = 7.78), this shows that the anchor model is 
uniformly better than the linear model (√𝑀𝑆𝑃𝐸 = 12.95) for this data. 
Finally, we compare the anchor model to that of a logistic transform model. The logistic 
transform is a model that is more advanced yet also more difficult to calculate and interpret. We 
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fit the logistic transform model by taking each ALSFRS-R score, dividing it by its maximum of 
48, and fitting the resultant data (that is bounded between 0 and 1) with a logistic regression 
model. In other words, for a given patient we fit the following model: 𝑙𝑜𝑔𝑖𝑡 (
𝑦𝑖
48
) = 𝛽0 + 𝛽1𝑥𝑖 +
𝜖𝑖𝑗, where 𝜖𝑖𝑗 are independent errors that follow 𝑁(0, 𝜎
2), 𝛽0 and 𝛽1 are the intercept and slope 
parameters, 𝑥𝑖 is the time-point associated with ALSFRS-R score 𝑦𝑖. The MSPE of this model 
comes to be 14.65, significantly higher than the MSPE for either the standard OLS model or the 
anchor model. 
1.4 Discussion 
In this paper, we discussed a simple and computationally inexpensive technique that may 
improve the predictive power in linear models. This method consists of creating an additional 
assumed data point, referred to as an anchor, and including it in the OLS regression. It has been 
shown in this paper that including an anchor theoretically decreases prediction variance at the 
cost of potentially increased bias. We demonstrated how using an anchor can improve linear 
predictions from modelling disease progression in ALS patients. 
Fitting the anchor model can be performed as easily and efficiently as a standard OLS 
regression, yet it has the potential to be a much stronger predictive model. Furthermore, the 
interpretations of the anchor model’s parameters remain largely unchanged from that of OLS 
regression, which is a huge advantage over other models. The interpretability of the parameters is 
arguably one of the most attractive parts of linear models.  
We imagine that using an anchor in the way we have demonstrated will be of particular 
use when modelling a bounded linear process where one can obtain a measure of when the 
process first began and/or ended. The bounds give a justification for choosing the 𝑦-value of the 
anchor; without bounds it may be difficult to justify a value without first looking at the data, 
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potentially leading to overfitting. However, as long as monotonicity approximately holds, one 
could still use something such as the 99
th
 percentile of the response if no bound exists. 
While the results in this paper are done under the assumptions of frequentist OLS 
regression, it is in no way limited to this. The idea of using this additional data point easily can 
extend to other families of models such as generalized linear models, hierarchical models, and 
mixed models. For example, one dramatically can improve the model performance in the ALS 
example by switching from independent linear regressions for each patient to a Bayesian 
hierarchical model; this allows patients to borrow information from one another and results in 
improved estimators due to shrinkage (11). This model is improved even further when it 
becomes a Bayesian hierarchical model that uses an anchor for each patient (12). 
Deciding when to include an anchor for modelling is not straightforward. If the goal is 
estimation, the induced bias may not be worth the reduced variability in estimates. While we 
developed a theoretical bound for when an anchor will improve the MSPE, it depends on having 
theoretical knowledge of the underlying linear process, which is rarely possible in practice. Thus, 
we recommend using cross-validation to compare using an anchor versus a more standard 
approach, as we performed in our ALS example. Because some sort of cross-validation is good 
standard practice when evaluating predictive models, we feel that this is a very small price to pay 
for a potentially dramatic improvement in predictive error. 
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Chapter 2: Using an Onset-Anchored Bayesian Hierarchical Model to Improve Predictions 
for Amyotrophic Lateral Sclerosis 
2.0 Abstract 
Background: Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is a 
rare disease with extreme between-subject variability, especially with respect to rate of disease 
progression. This makes modelling a subject’s disease progression, which is measured by the 
ALS Functional Rating Scale (ALSFRS), very difficult. Consider the problem of predicting a 
subject’s ALSFRS score at 9 or 12 months after a given time-point.  
Methods: We obtained ALS subject data from the Pooled Resource Open-Access ALS Clinical 
Trials Database, a collection of data from various ALS clinical trials. Due to the typical linearity 
of the ALSFRS, we consider several Bayesian hierarchical linear models. These include a 
mixture model (to account for the two potential classes of “fast” and “slow” ALS progressors) as 
well as an onset-anchored model, in which an additional artificial data point, using time of 
disease onset, is used to improve predictive performance.  
Results: The onset-anchored model had a drastically reduced predictive mean-square-error, 
when compared to the Bayesian hierarchical linear model or the mixture model under a cross-
validation approach.  No covariates, other than time of disease onset, consistently improved 
predictive performance in either the Bayesian hierarchical linear model or the onset-anchored 
model. 
Conclusions: Augmenting patient data with an additional artificial data point, or onset anchor, 
can drastically improve predictive modelling in ALS by reducing the variability of estimated 
parameters at the cost of a slight increase in bias. This onset-anchored model is extremely useful 
if predictions are desired directly after a single baseline measure (such as at the first day of a 
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clinical trial), a feat that would be very difficult without the onset anchor. This approach could be 
useful in modelling other diseases that have bounded progression scales (e.g. Parkinson’s 
disease, Huntington’s disease, or inclusion-body myositis). It is our hope that this model can be 
used by clinicians and statisticians to improve the efficacy of clinical trials and aid in finding 
treatments for ALS. 
2.1 Introduction 
Amyotrophic Lateral Sclerosis (ALS) is a rare neuro-degenerative disease that exhibits 
extreme between-subject variability. Progression of ALS typically is measured by the ALS 
Functional Rating Scale (known as the ALSFRS), or with additional respiratory questions (the 
revised ALSFRS-R). The ALSFRS is a physician-reported outcome on a scale of 0 – 40 that 
grades common activities of daily living like dressing, eating, and walking. An ALSFRS score of 
40 corresponds to normal function, and this score will decrease as the disease progresses. The 
ALSFRS, that is usually non-increasing,  has been shown to decrease in a linear fashion over the 
course of a typical clinical trial (6 months to 1 year) (1, 2), although the linearity is disputed over 
long periods of time (3).  
Faster disease progression consistently is associated with lowered survival (2, 4-8). Many 
of the clinical measurements shown to be associated with survival (e.g. region of symptom onset 
and Riluzole use) are not significantly associated with disease progression (9-11). Riluzole is the 
only FDA-approved drug for ALS. As rates of progression on the ALSFRS often are used in 
phase II and III clinical trials, more accurate predictive models would help researchers in 
improving trial efficiency.  
Our aim was to develop a predictive Bayesian hierarchical model that could be used to 
predict individual ALSFRS scores at one year from trial beginning using at most the first three 
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months of clinical trial data. Our baseline model is a Bayesian hierarchical linear model, which is 
similar to a linear mixed effects model. We then compared the predictive power of this baseline 
model to those provided by a Bayesian mixture model and a Bayesian onset-anchored 
hierarchical linear model. The onset-anchored model leverages an additional data point for each 
patient, which assumes maximum ALSFRS score at the time of disease onset. Note that the 
approach of using an onset-anchor is applicable in modelling other diseases that use a bounded 
rating scale (Parkinson’s disease, Huntington’s disease, etc.). We additionally consider variable 
selection to improve model predictive accuracy, as well as consider model robustness when less 
than three months of data are available. 
2.2 Methods 
Study population.  The datasets analyzed during this study are available in the Pooled 
Resource Open-Access ALS Clinical Trials database (PRO-ACT) 
(https://nctu.partners.org/ProACT/) (12).  In 2011, Prize4Life, in collaboration with the 
Northeast ALS Consortium, and with funding from the ALS Therapy Alliance, formed the PRO-
ACT Consortium. The data available in the PRO-ACT Database have been volunteered by PRO-
ACT Consortium members. As of December 2015, PRO-ACT had 4,838 unique subjects, each 
having at least one reported ALSFRS or ALSFRS-R score. As PRO-ACT is a collection of data 
from clinical trials, we further subset this data only to include subjects that were receiving 
placebos. This resulted in 1,301 subjects to be considered for analysis. One patient was dropped 
later due to having no data entered for disease onset time, bringing the final number of subjects 
to 1,300. For more demographic information on these subjects, see Table 2.1.  
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Categorical Counts 
Sex Male: 812  Female: 488 
 Race White: 1218 Black: 22 Latino: 13 
 
Asian: 12 Indian: 1 Other: 34 
Riluzole Use Yes: 600 No: 358  Not Reported: 342 
 Continuous Mean SD 
 Age (at trial start) 55.5 11.9 
 Onset Time (days from trial start) -658.4 456 
 Number of ALSFRS scores 9.3 4.5 
  
Table 2.1:  Demographic data for n=1,300 ALS subjects from the PRO-ACT database considered 
for analysis. 
For these 1,300 subjects, we used ALSFRS scores to measure disease progression. The 
ALSFRS score is bounded between zero and 40, and typically is non-increasing. Patients with 
ALSFRS-R scores, the revised ALSFRS, had their scores converted to the ALSFRS by summing 
the scores from the first nine questions of the ALSFRS-R (that concern motor and bulbar 
function) as well as the score from the first respiratory question, R1: Dyspnea. 
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Model comparison. Our objective was to build a predictive model with which we could 
use the first three months of a subject’s data to determine their ALSFRS score at one year. As 
very few subjects had a measurement at exactly one year, we instead used the model to predict 
each subject’s first score after day 365, denoted as 𝐹𝑅𝑆365. Three months was chosen as the 
cutoff because: 1) this was the window used in the DREAM ALS Stratification Prize4Life 
Challenge; 2) three months represented a reasonable amount of time for making 12-month 
predictions; and 3) this was a time frame with utility for both adaptive trial designs and for 
imputing missing data. Ideally, this model would be accurate even when less than three months 
of subject data are available.  
Large amounts of variability are inherently associated with any ALS model. Bayesian 
hierarchical models excel at capturing many sources of variability that can be reported via 
posterior predictive credible intervals. A credible interval is preferable for its interpretability; in 
the framework of a Bayesian model, there is a 95% chance that a subject’s 𝐹𝑅𝑆365 is within the 
95% credible interval. Note to control the type I error rate, the gold standard for confidence 
intervals is 90% or 95%. A credible interval, being a statement of probability, has no such 
restriction, and thus is useful with even lower credible levels, such as 70% or 80% (13). 
We considered three types of models that are described below: A Bayesian hierarchical 
linear model, a Bayesian hierarchical mixture model, and a Bayesian onset-anchored hierarchical 
linear model. Note that these models are all linear with respect to time. This is largely because a 
patient in PRO-ACT typically has only one ALSFRS measurement per month, which causes 
more complicated models, such as 3-parameter sigmoidal curves, to suffer from convergence 
problems. Linearity also is convenient because the slope parameter can be used as a simple-to-
interpret measure of the disease’s rate of progression. 
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The models were compared using their posterior mean-square-error (MSE) that resulted 
from a cross-validation analysis. Cross-validation entails splitting the data into a training set with 
which to build the model, and a validation set with which to assess the model’s predictive power 
(13). The MSE is defined as the sum of the squared difference between the predicted 𝐹𝑅𝑆365 and 
the observed 𝐹𝑅𝑆365 for each subject in the validation set, and is adjusted for the size of the 
validation set.  
In order to be in the validation set, subjects needed at least one ALSFRS score after one 
year from baseline. Again, as the ALSFRS score at one year specifically was not observed for 
most patients, we instead predicted 𝐹𝑅𝑆365, the subject’s first score after 365 days. Of subjects 
who had at least one year of data, average 𝐹𝑅𝑆365 was 386.7 days, with standard deviation of 
23.7 days and maximum of 577 days. The same training and validation sets were used to validate 
all three models. 
 All analyses were done using R (14), OpenBUGS (15), and the R package R2openBUGS 
(16). Pseudo-code that describes the model in more detail is provided in the appendix (A2). 
Bayesian hierarchical linear model. Since ALS seems to progress linearly over most 
one year time frames in the PRO-ACT database, we started with a linear hierarchical Bayes 
mixed effects model with weak and uninformative priors. Specifically, the ALSFRS for subject 𝑖 
at time 𝑡 is modeled as: 
𝐴𝐿𝑆𝐹𝑅𝑆𝑖(𝑡)~𝑇3(𝑎𝑖 + 𝑏𝑖𝑡, 𝜎
2) 
restricted to 𝐴𝐿𝑆𝐹𝑅𝑆𝑖(𝑡) ∈ [0,40], that easily is done in OpenBUGS. 𝑇3 denotes the centered 
non-standardized t-distribution with three degrees of freedom and non-standardized variance 𝜎2. 
Note that a standardized t-distribution with three degrees of freedom would instead have a 
variance of one. Parameters 𝑎𝑖 and 𝑏𝑖 are the subject-specific intercept and slope term. A t-
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distribution with three degrees of freedom was chosen because a normal distribution was too 
narrow in the tails. Additionally, we observed that the residuals from simple linear regression on 
subjects (with sufficient amounts of data) followed a 𝑇3 distribution extremely well (see Figure 
2.1). 
 
Figure 2.1: QQ plots for the residuals obtained from fitting simple linear regression models on 
subjects that had at least 5 ALSFRS measurements. 
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Where 𝑏𝑖 is restricted to be non-positive. Weak priors from the literature and discussions with 
clinicians were assumed for 𝑝0 and 𝑝1. Specifically, Castrillo-Viguera et. al. (17) reported that 
the ALSFRS-R decline in one database is roughly -0.92 units per month with a standard error of 




    𝑝1~𝑁(−0.025, 0.3
2) 
Where the increased error in 𝑝1 allows for more strength in the analysis to come from the data. 
Generally subjects with low baseline ALSFRS scores are not enrolled in clinical trials, and the 
prior for 𝑝0 was chosen to reflect this while still allowing a wide range of potential starting 
ALSFRS values. Uninformative priors were assigned to the remaining variables.  
Such a Bayesian model, aside from the weakly informed priors on 𝑝𝑖, was suggested by 
Gomeni et al. (18) . A key advantage to hierarchical modelling in this way is that it allows for 
shrinkage of error resulting from sample means (19, 20), and also lets subjects with fewer data 
points “borrow” information from the remaining population. The Bayesian analysis also has 
advantages with respect to interpretability (especially in a clinical setting). This model will be 
referred to as the “linear model”.  
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Bayesian hierarchical linear mixture model. A mixture model is useful when each 
subject belongs to one of several groups, each group having their own specific progession 
distributions. Specifically, Gomeni et al. (18), suggested that ALS subjects could be classified as 
either “fast” or “slow” progressors. To model this, we assume each subject is either a fast or slow 
progressor, and assume that each group has their own average rate of disease progression 
(parameterized by the mean of the subject-specific slope). We further assume the slope 
parameter for fast progressors strictly is steeper (more negative) than those of slow progressors. 
 The ALSFRS for subject 𝑖 at time 𝑡 is still 𝐴𝐿𝑆𝐹𝑅𝑆𝑖(𝑡)~𝑇3(𝑎𝑖 + 𝑏𝑖𝑡, 𝜎
2), but now we let 
𝑏𝑖~𝑁(Λ, 𝜎1
2). This starts the mixture process, with Λ being either Λ1 or  Λ2 = (Λ1 + 𝑐), where 𝑐 
is a positive constant, with probability Pr(Λ = Λ𝑖) = 𝜋𝑖. Finally, we use the following priors, 
𝜋𝑖~𝐷𝑖𝑟𝑖𝑐ℎ𝑙𝑒𝑡(1,1), Λ1~𝑁(0, 𝜎Λ1). The remaining parameters from the mixture, such as 𝑐 and 
𝜎Λ1, are assigned uninformative positive priors . All other priors and parameters are specified as 
in the linear model (2.2.1). This model shall be referred to as the “mixture model”.  
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Bayesian onset-anchored hierarchical linear model. This model resembles the linear 
model in structure, but uses an idea first introduced by Proudfoot et al. (21). The idea was to 
create an additional artificial data-point, referred to as the “onset-anchor”. We do this by 
assuming that each subject had an ALSFRS score of 40 (the maximum possible score) at their 
time of disease onset (see Figure 2.2). Aside from this artificial data point, the parameters and 
model specification remain identical to those given in the linear model. This model is referred to 
as the “onset-anchored model”.   
 
Figure 2.2: Ordinary least-squares estimates for two models: the linear model uses data from 
zero to three months only, while the onset-anchored model includes an additional artificial data-
point. This time point is given as (𝑥, 𝑦) = (time-point of disease onset-time, maximal ALSFRS 
of 40). 
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Assuming the maximum possible ALSFRS score at disease onset time was an idea first 
introduced by Proudfoot et al. (21). They used this assumption to create a slope between the 
onset anchor and the first observed ALSFRS score that then was used as a predictor for 
measuring a patient’s disease progression. Our onset-anchored model, however, treats this 
additional artificial data point as an observed value (specifically, a leverage point) in the 
modelling framework. 
Considering the simplicity of this approach, the addition of a non-random leverage point 
to aid in model prediction is a surprisingly novel technique. This method will, however, result in 
a biased linear regression model.  Recall that the MSE of any prediction is composed of the sum 
of the square of the bias and the variance of the prediction. In order for this biased model to 
predict 𝐹𝑅𝑆365 well, the reduction in prediction variance needs to dramatically outweigh the 
increase in prediction bias.   
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Covariate selection using the onset-anchored model. After choosing a “winner” from 
the three models mentioned above (the onset-anchored model), we wished to determine which 
clinical features, if any, improved predictive accuracy when used as covariates in the model. 
Clinical features considered were height, symptom onset time, sex, age, race, individual sub-
questions of the ALSFRS, forced vital capacity (FVC, both liters and percent predicted of 
normal), respiratory rate, weight, Riluzole use (yes/no), and site of onset (bulbar/limb). Many lab 
measurements are included in PRO-ACT, yet due to their sparse nature, only lab features that 
were present in at least 90% of the subjects were considered. Albumin has been shown to be 
associated with ALS survival (22) and was included for analysis even though it was only present 
in 86% of subjects. The following lab features were considered in our analysis: chloride, serum 
aspartate aminotransferase (AST), glucose, sodium, blood urea nitrogen (BUN), potassium, 
bilirubin, alanine transaminase (ALT), creatinine, and albumin. 
Many of these features were repeated measures. To use them as covariates, they were 
truncated to at most three months, then collapsed to slope and intercept (baseline) measures. 
Specifically, we performed a linear regression on the feature with respect to time, and extracted 
the ordinary least squares estimates for the slope and intercept. While true baseline data would be 
preferable over the ordinary least squares intercept estimator, baseline data were frequently not 
available. Therefore the ordinary least squares intercept estimator was chosen for homogeneity. 
Collapsing longitudinal predictors has been successfully employed in other ALS predictive 
models (23, 24), and greatly simplifies the modeling process. All features were normalized using 
their sample means and variances for ease of analysis and interpretability.  
As we were more interested in predictive power, our criteria for feature selection was 
improvement to the average MSE resulting from predicting 𝐹𝑅𝑆365 in repeated cross-validation 
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analysis (using 90% of the data as the training set and 10% as the validation set), rather than the 
statistical significance given by a small p-value. Deviance information criterion (DIC) also was 
considered in assessing whether features improved the model or not. 
To assess each covariate we randomly subset the overall data into 300 subjects with non-
missing entries. While multiple imputation could be used here, we chose only to use complete 
cases to drastically reduce computation time as well as eliminate potential convergence 
problems. We then used cross-validation on this subset of 300 subjects to obtain posterior 
distributions of the MSE for the onset-anchored model using the covariate and the baseline 
onset-anchored model for which did not use the covariate. The average difference in MSE 
between the two models then was computed, and this entire process (starting with subsetting to 
300 subjects) was repeated 100 times for each covariate. Specifically, we compared the average 
difference in MSE of the following two models (for the full model specification, see appendix 
A1): 
Covariate onset-anchored model: 
𝐴𝐿𝑆𝐹𝑅𝑆𝑖(𝑡)~𝑇3(𝑏0𝑖 + 𝑏1𝑖𝑡, 𝜎
2) 
                 𝑏0𝑖~𝑁(𝑝00 + 𝑝01𝑋𝑖, 𝜎0
2) 
                 𝑏1𝑖~𝑁(𝑝10 + 𝑝11𝑋𝑖, 𝜎1
2) 
  
Baseline (no covariate) onset-anchored model:  
𝐴𝐿𝑆𝐹𝑅𝑆𝑖(𝑡)~𝑇3(𝑏0𝑖 + 𝑏1𝑖𝑡, 𝜎
2) 
                 𝑏0𝑖~𝑁(𝑝00, 𝜎0
2) 
                 𝑏1𝑖~𝑁(𝑝10, 𝜎1
2) 
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Where 𝑋𝑖 is the subject-specific covariate, 𝑡𝑖 is time for subject 𝑖. The slope of subject 𝑖 is 
𝑏1𝑖 which, in the covariate model, is a function depending on 𝑋𝑖. Similarly, 𝑏0𝑖 is the subject-
specific intercept. As per hierarchical modelling, we assume priors only for the hyper-parameters 





Uninformative priors were assigned for the remaining parameters in both models.   
 
2.3 Results 
We investigated the predictive power of three types of Bayesian hierarchical models: 
linear, mixture, and onset-anchored. In a Bayesian framework, when cross-validating a model, 
the resultant MSE has a posterior distribution that takes into account all of the sources of 
variation within the model. Specifically, these sources of variation include: 1) variation within 
the model; 2) variation of the posterior parameters; and 3) the variation of the posterior 
predictive distribution. Therefore, it is important not only to lower the MSE but also to decrease 
its variance. Of the three models, the onset-anchored model not only had the smallest MSE but 
also had the MSE with the smallest variance (Figure 2.3). Note that the DIC between the onset-
anchored model and the standard linear model cannot be compared, because the additional data 
point in the onset-anchored model results in a different likelihood.  
The MSE for the onset-anchored model not only is smaller in terms of expectation (In Figure 
2.3 the means of the MSE for the onset-anchored, mixture model, and linear model were 51.1, 
68.5, and 73.7 respectively) but also has the smallest variance. We also considered a mixture 
model that utilized the additional data point given by the onset anchor. This complex model 
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performed about as well as the more parsimonious onset-anchored model, that can be seen by 
their nearly overlapping MSE distributions in Figure 2.3.  
 
Figure 2.3: Comparison of posterior MSE distribution for four types of hierarchical models: 
linear, onset-anchored, mixture, and mixture with the additional data-point used in the onset-
anchored model. This is from a single cross-validation analysis, but this separation of 
distributions is typical. 
We next attempted to find which covariates or features could consistently improve the 
MSE of the onset-anchored model, or decrease the DIC.  While many clinical and lab predictors 
had nonzero effects on the posterior slope and intercept (meaning 𝑝11 and/ or 𝑝01 were nonzero), 
very few predictors consistently improved the MSE, and among those that did, the improvement 
to the MSE was very small (Table 2.2). Some variables, such as FVC: Subject Liters (slope) and 
forced vital capacity (FVC): Percent Normal (slope) reduced DIC (each reduced DIC by about 
3.45); however, they did not contribute towards a meaningful improvement in predictive power. 
Of the 53 covariates tested, only “disease onset time” resulted in an improvement to the MSE 
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that was on average greater than one percent. This is most likely due disease-onset time giving a 
slight bias correction to the model. The next best covariates were subject’s 3-month slope of 
FVC (in raw liters) and 3-month slope of the first question from the ALSFRS: Q1, Speech.  
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Covariate Name 
Median % MSE 
reduction (negative values 
signify an increase to the 
MSE) 
IQR for % 
MSE 
reduction 
Mean DIC adjustment 
(larger values result in 
larger DIC) 
Onset Time 0.0174 0.027 2.8 
FVC: Subject Liters (slope) 0.0095 0.02 -3.5 
Q1: Speech (slope) 0.0081 0.0187 0.8 
Diagnosis Time 0.0059 0.0183 -2.1 
Q7: Turning in Bed(slope) 0.0052 0.0182 -3.5 
Q8: Walking (slope) 0.0052 0.0254 -2.2 
AST (slope) 0.0043 0.0179 -0.3 
Q5: Cutting (slope) 0.0043 0.0202 -1.5 
Q6: Dressing/Hygiene (slope) 0.0039 0.0223 -1.9 
ALT (slope) 0.0034 0.0166 0.1 
Q2: Salivation (slope) 0.0032 0.0195 1.7 
Q9: Climbing Stairs (slope) 0.003 0.0232 -2 
AST (intercept) 0.0028 0.0162 0.8 
FVC: Percent Normal (slope) 0.0025 0.0225 -3.4 
Race 0.0021 0.0156 -0.1 
ALT (intercept) 0.0021 0.0182 -0.7 
Bilirubin Total (slope) 0.0019 0.0196 -0.5 
Respiratory Rate (intercept) 0.0017 0.0146 0.3 
Q2: Salivation (intercept) 0.0013 0.0203 -1.4 
Creatinine (intercept) 0.0011 0.0152 -0.7 
Age 0.001 0.0185 -2.1 
Q1: Speech (intercept) 0.001 0.0224 2.2 
Potassium (slope) 0.001 0.0136 -0.9 
Onset Site: Bulbar 0.001 0.0171 -0.5 
Height 0.0009 0.0169 0.8 
Weight (slope) 0.0009 0.0174 -1.7 
Sodium (intercept) 0.0008 0.0188 1 
Bilirubin Total (intercept) 0.0008 0.0183 0.8 
Sex 0.0006 0.0169 -0.4 
Q10: Respiratory (slope) 0.0006 0.0153 0.8 
Q4: Handwriting (slope) 0.0006 0.0206 -0.7 
Weight (intercept) 0.0006 0.0181 -0.5 
Q5: Cutting (intercept) 0.0002 0.0224 -4.1 
Table 2.2: Median reduction to MSE, in percentage, for covariates which improved the MSE.  
The inter-quartile range for the percent reduction as well as average difference in DIC is shown 
as well. 
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Recall that several of these clinical values have been found to be associated with survival, 
including Forced Vital Capacity (FVC), age of onset, and site of onset (bulbar or limb, which can 
help differentiate subtypes of ALS). However, none of these covariates have been consistently 
useful for modelling ALSFRS progression (9); this is consistent with our findings. Riluzole use, 
in particular, worsened MSE by a median of 0.09% (see appendix A3 for expanded Table 2.2). 
Again, this is not surprising as Riluzole has only a weak effect on survival and has not been 
shown to be consistently associated with decreased disease progression (10, 25).   
To appropriately predict the ALSFRS for a given subject at one year from trial onset 
using data collected up to three months after trial onset, a measure of uncertainty must be 
reported as well. Since a Bayesian analysis instead was performed, we can obtain 95% credible 
intervals for each subject’s 𝐹𝑅𝑆365. Figures 2.4 and 2.5 give a sample of posterior distributions 
from a cross-validation for nine randomly-selected subjects’ 𝐹𝑅𝑆365, as well as their 95% 
credible intervals and true 𝐹𝑅𝑆365 (the subject’s first score at, or after, 365 days). To further 
demonstrate the improved predictive power of the onset-anchored model, this is done for both 
the standard linear model (Figure 2.4) as well was the onset-anchored model (Figure 2.5).  
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Figure 2.4: Posterior predictive distributions for a random sample of subjects’ 𝐹𝑅𝑆365 obtained 
through cross-validation utilizing the standard linear model. 
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Figure 2.5: Posterior predictive distributions for a random sample of subjects’ 𝐹𝑅𝑆365 obtained 
through cross-validation utilizing the onset-anchored model. 
It can be noted that the credible intervals for the linear model are very wide, 
encompassing nearly the full range of the disease. The onset-anchored model drastically reduces 
the length of these credible intervals. In repeated cross validation, the 95% credible interval 
contained the true 𝐹𝑅𝑆365 for a given subject roughly 73% of the time. As the time of data 
collection used to make the prediction increases from three months, this prediction becomes 
more accurate.  
The performance of the onset-anchored model vastly is superior to that of the linear 
model when the length of time for data collection is short. Figure 2.6 shows that the onset-
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anchored model, using only baseline data, typically outperforms a linear model using many 
months of subject data. Figure 2.6 also shows that the onset-anchored model performs well even 
when the window for data capture is restricted to less than three months, including when only a 
baseline measurement is available for each subject.  
 
Figure 2.6: The effect of changing the number of months of data used for prediction in both the 
linear and onset-anchored models. This effect is measured by the MSE (and associated 90% 
credible interval) resulting from a single cross-validation analysis for both models. 
Recall that, while MSE of prediction drastically is reduced when using the onset-
anchored model, it is in fact a biased model. The additional data point causes the model typically 
to underestimate the rate of disease progression, resulting in a higher predicted 𝐹𝑅𝑆365 than 
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observed. Using the onset-anchored model resulted in a prediction bias of, on average, about two 
(on the ALSFRS scale). For comparison, the linear model typically was unbiased.  
Finally, it is typical to measure progression of ALS by the slope of the ALSFRS. An 
advantage to using the Bayesian framework is that the ALSFRS slope for subject 𝑖, defined 
previously as 𝑏1𝑖, is specified in the model likelihood, and therefore, has a posterior distribution. 
Thus, one can then obtain a posterior estimate and credible interval for slope from this 
distribution. In other words, when using this model one easily can predict slope for a given 
subject in addition to 𝐹𝑅𝑆365. Examples of the posterior predictive distributions for the ALSFRS 
slope using three months of data, with 90% credible intervals, is provided in Figure 2.7 for the 
same nine subjects used in Figures 2.4 and 2.5. As the onset-anchored model performs well even 
when using only baseline data, subject slopes could be predicted using this model as soon as a 
baseline ALSFRS score has been established.  
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Figure 2.7: Posterior predictive distributions for a random sample of subjects’ ALSFRS slope 
obtained through cross-validation utilizing the onset-anchored model. The regression estimate of 
the ALSFRS slope (dotted line) was calculated using ordinary least squares on subject’s full 
data. 
2.4 Discussion 
We explored three different Bayesian hierarchical predictive models with the goal of 
modelling ALS disease progression. These models were linear, mixture, and onset-anchored. The 
onset-anchored model that uses an additional data point by assuming the maximum ALSFRS 
score at time of disease onset (e.g. 40), is the best model in terms of predictive accuracy via 
cross-validation. This is especially noticeable when the window for data capture is very small, 
such as only using a baseline ALSFRS score.  
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While linear over the course of a typical clinical trial, progression of the ALSFRS could 
become curvilinear over long periods of time. This is reinforced further by the fact that it is 
bounded between zero and 40, and typically is non-increasing. Predictive models that attempt to 
account for this non-linear progression suffer from a disparity between the number of subject-
specific data points and the necessary number of model parameters. We hypothesize that using 
the onset-anchor helps to “balance” this prediction (see Figure 2.2), while also enabling 
shrinkage on the slope estimator. The result is a model that has reduced variability of parameter 
estimates (at the cost of a small increase in bias), which enables a large reduction in overall 
prediction MSE.  
Using three months of subjects’ data, we found that very few clinical features improved 
prediction as measured by the MSE of repeated cross-validation analysis. Among those features 
that did consistently improve the MSE, the improvement was rarely more than a one percent 
reduction. This corroborates findings by Creemers et al. (9) who found the quality of evidence 
among disease progression prognostic factors to be low at best. The covariate that offered the 
largest and most consistent improvement to the model’s prediction was disease onset time. As 
disease onset time is also a key part of the onset-anchor model, this stresses its importance and 
supports other studies that have shown onset time strongly is associated with disease progression 
as well as survival (5, 6, 23). 
From a practical point of view, a model that only requires time of disease onset and three 
months of progression data eases both patient and clinician burden by requiring less overall 
measurements.  The Bayesian modeling approach proposed here can help inform the design of 
adaptive studies, and can be used as an imputation scheme to conduct trials more quickly (26-
28). Finally patients with ALS are routinely interested in charting their own progression, as well 
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as trying interventions that might include treatments for spasticity or pain, or supplements geared 
towards slowing disease progression. In conjunction with a self-administered ALSFRS, the 
onset-anchored model then becomes a predictive tool that an ALS patient can use aid them in 
tracking their disease and assess the utility of self-administered interventions. 
While the idea of using an additional data point as used by the onset-anchored model is 
simple, it is surprisingly novel. Creating biased models to improve predictive MSE is not 
uncommon, and is used in ideas like fixed-point regression or ridge regression. However, using 
an artificially created data point and treating it as observed data is something that, to the best of 
our knowledge, is something that has never been used before. We have found no literature where 
it theoretically is discussed or practically used. This methodology could be applied to any 
longitudinal data where the onset time of the process being modelled is known. Other diseases 
that have bounded rating scales that measure progression, including Parkinson’s disease or 
Huntington’s disease, might benefit tremendously from predictions that use an onset-anchor. 
One limitation to the current study is that subjects who died before the clinical trial had 
progressed a full year were not candidates for cross validation, and hence did not directly 
contribute to the MSE. However, the Bayesian framework allows these subjects to be included in 
building the model, where their often-increased rates of disease progression contribute to the 
variability of the model. Specifically, subjects who died prior to one year still contributed 
towards key model variables, including the distributions of rate of progression, effects of 
covariates, and variability measures throughout the model. Subjects who died prior to one year 
also had, on average, a lower predicted 𝐹𝑅𝑆365 than subjects who survived past one year. This is 
expected since a faster progression is associated with lowered survival. 
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Another limitation is the width of the posterior predictive distributions among individual 
subjects’ 𝐹𝑅𝑆365. These distributions express a combination of variation within the model, 
variation of the posterior parameters, and variation of the posterior predictive distribution. Due to 
the heterogeneity of ALS, it is not unexpected that 𝐹𝑅𝑆365 can range widely at the individual-
patient level. This will remain a limitation of any predictive model until better factors that more 
strongly are associated with disease progression (rather than survival) are discovered.  
The onset-anchored model’s inherent bias is another limitation of the model. This is the 
typical concern with any biased linear model, but in this case we can see that the reduction in the 
onset-anchored model’s MSE is worth the tradeoff. A possible solution might be to investigate a 
bias-correction term that would utilize disease-onset time as well as the number of days after the 
start of the trial that is associated with 𝐹𝑅𝑆365.  
One final limitation worth pointing out is that disease-onset time, a critical feature of the 
onset-anchored model, is a problematic variable. This variable typically comes from patient 
memory, and as a result is subject to recall bias. Proudfoot et al. point out that while this bias 
exists, using patient-recalled onset time is still a useful predictor for disease progression (21), 
and this is corroborated by our model. 
2.5 Conclusions 
In this paper we considered the problem of predicting an ALS patient’s ALSFRS score at 
one year, given up to three months of data. Three different Bayesian hierarchical predictive 
models were considered: linear, mixture, and onset-anchored. The onset-anchored model that 
leverages an additional artificial data point that assumes the maximum ALSFRS score of 40 at 
the patient’s time of disease onset, is the best model with respect to predictive accuracy under 
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cross-validation. The onset-anchored model is simple to implement, and potentially is applicable 
to various other diseases that measure progression by bounded rating scales. 
The effect of many covariates (lab values, demographic information, etc.) on these 
predictions was assessed via repeated cross-validation. The result is that time of disease onset is 
the only covariate that provides a consistent improvement to predictions, but this is a very small 
improvement. This highlights the urgent need to develop a better understanding of the 
mechanism behind ALS progression.  
The onset-anchored model has an added benefit over the other models in that it allows 
predictions to be made as soon as a patient has a baseline ALSFRS score. In other words, as soon 
as the first ALSFRS measure is taken in a clinical trial, the model can be utilized for endpoint 
prediction of the ALSFRS. We hope this model can be used by clinicians and statisticians to 
improve the efficacy of clinical trials and aid in finding treatments for ALS.  
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Chapter 3: Automated Data Extraction of Electronic Medical Records to Model ALS 
Survival and Progression   
3.0 Abstract 
Objective: To assess the feasibility of using automated capture of Electronic Medical Record 
(EMR) data for future amyotrophic lateral sclerosis (ALS) clinical research by comparing a 
University of Kansas Medical Center (KUMC) ALS data to an established ALS clinical trial 
population provided by The Pooled Resource Open-Access ALS Clinical Trials database (PRO-
ACT).  
Methods: We used an Informatics for Integrating Biology and the Bedside search discovery tool 
to identify and extract 219 ALS patients from the KUMC EMR, which were compared to 1300 
placebo-arm subjects from PRO-ACT. Bayesian hierarchical modelling provided estimates of 
disease progression as measured by the ALS Functional Rating Scale. Two different Cox 
proportional hazards models were used to investigate the effect of KUMC membership on 
survival. 
Results: KUMC patients were typically older at disease onset, were more likely to have bulbar 
onset, had slower ALS progression, and had improved survival rates versus subjects in PRO-
ACT. We found the following to be associated with improved survival: younger age, more time 
from ALS onset to baseline measure, limb (versus bulbar) onset, and higher baseline BMI, 
forced vital capacity, and ALS Functional Rating Scale scores.  
Conclusion: We show the feasibility of using automated data extraction from the EMR to model 
and track disease progression in ALS.  Differences in disease progression and survival in the 
KUMC patients compared to the PRO-ACT placebo controls highlight the need to better 
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understand disease variability in the clinical setting, and to refine the inclusion criteria in ALS 
trials. 
3.1 Introduction 
Amyotrophic Lateral Sclerosis (ALS) is a fatal neuro-degenerative disease. While over 
50 clinical trials have been conducted over the last two decades, none have been successful save 
riluzole and edaravone, that at best offer modest improvements in survival or function (1). While 
many studies may have failed because the drugs were ineffective, a recurring theme in ALS is 
underpowered trials with indeterminate results.  Two major hurdles to conducting ALS trials are 
the rarity of ALS (3.9 in every 100,000 people in the U.S. (2)) and the disease’s heterogeneity. 
Obtaining historic controls or creating predictive models from Electronic Medical Record 
(EMR) data would be one way to improve inexpensively the power and efficiency of ALS trials 
(3, 4). The wide use of EMRs, and the development automated abstraction of de-identified data, 
create opportunities to: 1) better understand ALS disease progression and determinates of 
survival in the clinical setting; 2) use clinical data to enrich existing placebo-arm data sets to 
improve the power of trials; and 3) leverage this electronic infrastructure to run clinical trials – 
including EMR-based screening, randomization, and data collection.  For these approaches to be 
valid, we need to demonstrate the feasibility of modeling disease progression using EMR-
captured clinical data.  
Here we compared statistical models built with EMR-captured patient data from our ALS 
clinic at the University of Kansas Medical Center (KUMC) to a typical ALS clinical trial 
population provided by The Pooled Resource Open-Access ALS Clinical Trials database (PRO-
ACT) (5). KUMC’s EMR is provided by Epic. 
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3.2 Methods 
Study design. We conducted a retrospective chart review of patients at the KUMC ALS 
Clinic. To do this efficiently, we used the KUMC Healthcare Enterprise Repository for 
Ontological Narration (HERON), powered by Informatics for Integrating Biology and the 
Bedside (i2b2), a discovery tool that allows searches of de-identified EMR data (6, 7). This 
allowed us to extract ALS patient data from the EMR for analysis, with records dating from 
summer 2012 to early 2017. This data include information on patient demographics, disease 
progression, and survival. Survival data captured by HERON comes from both the EMR and 
from the Social Security Death Index (8). This data then were verified and augmented by a 
manual chart review (Table 3.1).  
 Information extracted from 
HERON 




Subject age*, ethnicity*, race*, 
gender*, marital status, religion, 
date of birth 
Date of disease onset*, date of 




ALSFRS-R and its sub scores*, 
BMI*, FVC (raw and percent-
predicted)* 
Negative inspiratory force (NIF) 
Medication 
history 
 Riluzole*, Nuedexta, Vitamin use  
Other Death status*, date of death* Non-invasive positive pressure 
ventilation (NIPPV) status, date of 
NIPPV, NIPPV type 
Table 3.1: Specific data extracted from the KUMC EMR by HERON, and data added from 
manual chart review. Asterisk (*) denotes the data was also available in PRO-ACT. 
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Study populations. 
University of Kansas Medical Center (KUMC) ALS Clinic data. The ALS clinic at 
KUMC serves roughly four state regions across the Midwest (Kansas, Missouri, Oklahoma, 
Arkansas). At each visit, patient data collected by the clinician are entered in the EMR (EPIC 
EMR system, Epic Systems Corporation, 2015). Using HERON, we extracted data from patients 
who met the criteria of having at least one ALS Functional Rating Scale – Revised (ALSFRS-R) 
score, that measures ALS progression. Patients’ ALSFRS-R is recorded in-clinic by a research 
coordinator and entered into a document flow sheet. Only patients seen in the ALS specialty 
clinic with a known diagnosis of motor neuron disease have ALSFRS-R scores in the EMR. 
Initially, the KUMC data from HERON covered 357 subjects and 2,848 individual clinical visits. 
We eliminated patient encounters not pertaining to ALS, death, or respiratory progression. We 
further eliminated patients whose first and last ALSFRS-R scores occurred less than 90 days 
apart or had a diagnosis other than ALS (such as primary lateral sclerosis). This resulted in 219 
unique subjects and 960 clinical records.  
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Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) data. In 2011, 
Prize4Life, in collaboration with the Northeast ALS Consortium, and with funding from the ALS 
Therapy Alliance, formed the PRO-ACT Consortium. The data available in the PRO-ACT 
Database have been volunteered by PRO-ACT Consortium members 
(https://nctu.partners.org/PRO-ACT/) (5). We used PRO-ACT records prior to December 1, 
2015, which had 4,838 unique subjects with progression information (ALSFRS-R scores, or, 
more commonly, ALSFRS scores). Only subjects that were assigned to the placebo arm of their 
trials were considered so as to not contaminate our statistical models with unknown effects from 
various therapeutics. This resulted in 1,301 subjects and 11,773 patient records. Demographic 
information, including a comparison between the PRO-ACT data and the KUMC data, is given 
in the results section. 
Outcomes. The specific variables we obtained pertaining to demographic, disease 
progression, and survival are provided in Table 3.1. Disease progression of ALS typically is 
measured by the ALSFRS-R that consists of twelve physician-administered questions. Each 
question is on a 0 – 4 scale, with the overall score of 48 representing normal function (9). The 
ALSFRS-R has become the standard for measuring disease progression, and easily can be 
converted to the previous version, the ALSFRS. The ALSFRS, typically reported in older 
clinical trials, is the first 10 questions of the ALSFRS-R (meaning a score of 40 represents 
normal function on the ALSFRS).  
For this study, we utilized the ALSFRS (rather than the ALSFRS-R) in order to 
maximize the data available from the PRO-ACT database. Note that in ALS trials, the ALSFRS 
typically declines by one ALSFRS point per month (10). 
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Statistical methods.  
Disease progression. We used a Bayesian hierarchical linear model (with error terms 
following a 𝑇 distribution with three degrees of freedom) to model disease progression of the 
KUMC and PRO-ACT cohorts. While a Random Forest approach, such as performed by Taylor 
et al. (11), is accurate in predicting future ALSFRS-R scores, a hierarchical model allows us to 
easily estimate cohort-level disease progression rates. Quantile-quantile plots showed a 𝑇 
distribution with three degrees of freedom was more appropriate than the normal distribution for 
both the KUMC and PRO-ACT error terms.  
A linear model was selected due to the known typical linear decline of the ALSFRS (12, 
13) that was confirmed via visual inspection of the KUMC data. Some authors have disputed this 
in favor of a quadratic model (14, 15), but we found the quadratic term to be insignificant via 
deviance information criterion (DIC). A major advantage to utilizing a linear model is the 
convenience of using the ALSFRS slope parameter as an easily-interpreted measure of disease 
progression.  
The model is described as 𝐴𝐿𝑆𝑖(𝑡)~𝑇3(𝑎𝑖 + 𝑏𝑖𝑡, 𝜎
2), restricted to 𝐴𝐿𝑆𝑖 ∈ [0,40], with 
patient-specific intercept 𝑎𝑖~𝑁(𝑝0, 𝜎0
2) and slope 𝑏𝑖~𝑁(𝑝1, 𝜎1
2). This means the posterior 
distribution of 𝑝1 models the cohort-level disease progression. Weak priors were assumed from 
𝑝0 and 𝑝1 (Supplement Appendix A1), and 𝑏𝑖 was restricted to be non-positive. This approach is 
the Bayesian analogue to the linear mixed effects model.  
The predictive power of this model can be improved by using an “onset-anchor”. This is 
equivalent to augmenting each subject’s data with an additional fixed data-point given by 
assuming maximal ALSFRS score at time of their disease onset (16). This causes a slight bias in 
the model at the cost of drastically reduced variability. Since the mean squared error (MSE) of 
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prediction is equivalent to the sum of the variability (variance) and the square of the bias, a large 
reduction in variability at the cost of a slight increase in bias can result in models with superior 
predictions. We also adjusted for time of disease onset, which acts as a bias-correction term.  
Survival. We used disease-onset time as the baseline survival time for all patients rather 
than time of first clinical visit. This is necessary to create a common baseline time for measuring 
survival, as there is no reason to suggest that patients’ first clinical visit would be distributed 
equivalently across the two data sets. Survival then was modelled utilizing the Cox proportional 
hazards model. Note that time of disease onset typically is dependent on patients recalling when 
they first began having symptoms, which can be error-prone (16).  
An advantage to the Cox model is that we can test models that use several covariates at 
once. This allows us to consider the KUMC membership (versus PRO-ACT) effect on survival, 
after adjusting for other significant variables (17). To obtain such a model, we used a 
“backwards with forward looks” approach, only considering records without missing data.  
Covariates of interest were those that previously have been shown to be independently associated 
with survival in ALS. These include rate of ALS progression (15, 18-20), forced vital capacity 
(FVC) (21, 22), age at symptom onset (23, 24), site of symptom onset (13, 20, 23, 25), and body 
mass index (BMI) (22, 23). Specifically, we considered the following baseline covariates: sex, 
riluzole use, years from onset to baseline, age, FVC (percent predicted), BMI, ALSFRS score, 
diagnostic delay (months between disease onset and diagnosis of ALS), and site of disease onset. 
Certain data were omitted for extreme sparsity (such as negative inspiratory force) or for not 
being available in both data sets (such as marital status). All analyses were done using R (version 
3.2.4) (26) and OpenBUGS (version 3.2.3 rev 1012) (27). 
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3.3 Results 
Comparison of datasets. Race and gender were similar across the two datasets (Table 
3.2). Both were roughly 60% male and predominantly white, agreeing with reports published by 
the United States Center for Disease Control (CDC) (2). The typical site of disease onset was in 
the limbs, although limb onset was more prevalent in PRO-ACT. Both had roughly the same 
percentage of observed deaths; however,  the follow-up time for the KUMC patients was on 
average longer than those in PRO-ACT. KUMC patients had roughly half the average total 
number of clinical visits versus PRO-ACT subjects. 
 KUMC PRO-ACT 
Number of patients 219 1300 
Percent Female/Male 44/ 56 38/ 62 
Percent Caucasian / Non-Caucasian 90/ 10 94/ 6 
Percent Limb onset / Bulbar / Other 66/ 30/ 4 79/ 20/ 1 
Percent using riluzole Yes / No / Unknown 72/ 28/ 0 46/ 28/ 26 
Percent deceased during follow up 35 32.1 
Mean Follow-up time days (SD) 436.7 (309.5) 294.7 (164) 
Mean Age at disease onset (SD) 60.1 (11.4) 53.7 (12.0) 
Mean Number of months from onset to diagnosis (SD) 23.08 (33.45) 11.5 (8.8) 
Mean First recorded ALSFRS score (SD) 28.2 (6.3) 29.63 (5.8) 
Mean Years from onset to first clinical record (SD) 2.5 (3.2) 1.8 (1.3) 
Mean FVC percent predicted at baseline (SD) 69 (21) 78 (21) 
Mean BMI at baseline (SD) 27.37 (5.7) 25.6 (4.7) 
Mean number of visits (SD) 4.38 (2.27) 9.06 (4.4) 
Table 3.2: Comparison of KUMC and PRO-ACT information. Baseline is defined as the time of 
a patient’s first recorded ALSFRS score. 
Other differences between the two cohorts included: 1) average age at disease onset, that 
was older in the KUMC dataset; 2) subjects at KUMC had lower initial ALSFRS scores and 
baseline FVC (percent normal); 3) the number of months from disease onset to diagnosis 
(diagnostic delay) was longer in KUMC than PRO-ACT, with increased variability – a result of 
14 KUMC patients with diagnostic delay greater than five years, whereas PRO-ACT had only 
one.  
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Analysis of disease progression. Cohort-level disease progression was modelled by the 
posterior distribution of 𝑝1 (see methods), that portrays the possible ALSFRS slopes of a given 
cohort (Figure 3.1). We observed that PRO-ACT subjects had more rapid disease progression 
(typical difference of 0.17 ALSFRS points per month, or 2.00 points per year). The 90% credible 
interval for KUMC disease progression was (-0.89, -0.76), compared to (-1.02, -0.95) for PRO-
ACT. The only variable that consistently improved the predictions given by the model, via cross-
validation, was time of disease onset. 
 
Figure 3.1: Posterior estimates of cohort-level disease progression for KUMC and PRO-ACT 
patients, given both as kernel densities (A) and boxplots (B). As the progression is measured as 
the change in ALSFRS score per month, a more negative value corresponds to a more rapid rate 
of disease progression. 
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Analysis of survival. Median survival time from disease onset was 2.8 years for KUMC, 
compared to 2.2 years for PRO-ACT. The raw Kaplan-Meier survival curves (unadjusted for 
other covariates) obtained from the left-truncated, right-censored model is given in Figure 3.2. 
Note that the KUMC survival curve is never below the PRO-ACT survival curve, which allowed 
us to proceed with the Cox model. 
 
Figure 3.2: Kaplan-Meier survival curves for KUMC and PRO-ACT subjects. Where the 
horizontal line intersects the curve represents the median survival time, equivalent to where the 
y-axis is 0.5. 
The final Cox model for the two datasets included KUMC/PRO-ACT membership, 
riluzole use, years from onset to baseline, age at baseline, FVC at baseline (percent normal), 
BMI at baseline, and ALSFRS total at baseline. However, our modelling approach used complete 
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cases only (meaning subjects only were included if they had no missing data among the 
considered covariates), so this model includes only 78 of the 219 KUMC patients and 619 of 
1,300 PRO-ACT subjects. This is due to a large amount of missing baseline BMI and FVC 
information. The effects of each covariate, along with standard errors, are given in Table 3.3 
under “Model 1”. KUMC membership, longer time from onset to baseline, younger age, and 
larger baseline FVC, BMI, and ALSFRS resulted in an improved survival time. Riluzole use was 
associated with a relatively strong decrease in survival.  
Model 1 (Complete cases only) 
 
Covariate Fitted coefficient Standard error P-value 
KUMC membership -2.0136 0.2804 <0.0001 
Riluzole use  1.4540 0.1450 <0.0001 
Years from onset to baseline  -1.1557 0.1794 <0.0001 
Age (baseline)  0.0424 0.0061 <0.0001 
FVC (baseline, percent normal) -0.0229 0.0047 <0.0001 
BMI (baseline) -0.0599 0.0151   0.0001 
ALSFRS total (baseline) -0.0785 0.0116 <0.0001 
 
Model 2 (All subjects) 
 
Covariate Fitted coefficient Standard error P-value 
KUMC membership -0.7411 0.1418 <0.0001 
Years from onset to baseline -0.7369 0.1177 <0.0001 
Age (baseline)  0.0383 0.0042 <0.0001 
ALSFRS total (baseline) -0.1071 0.0071 <0.0001 
Site of onset (limb onset)  -0.3330 0.1020   0.0011 
Table 3.3: Coefficient values for the best fitting Cox survival models. Model 1 is found by only 
considering to complete cases (no missing data). This model may be misleading because it 
utilizes a small subset of the KUMC and PRO-ACT subjects. Model 2 utilizes all KUMC and 
PRO-ACT subjects but disregards baseline BMI and FVC as potential covariates. 
Eliminating baseline BMI and FVC in model selection (each are associated 
independently with survival after controlling for KUMC/PRO-ACT membership) results in a 
Cox model that utilizes all 219 subjects from KUMC and 1,300 from PRO-ACT. In this model, 
we again see that KUMC membership, longer time from onset to baseline, younger age, and 
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larger baseline ALSFRS resulted in an improved survival time (Table 3.3). Additionally, limb 
onset was associated with improved survival time. Note that the individual effect of group 
membership has been reduced greatly in this model; being in the KUMC cohort still results in 
improved survival, but the effect is not as before. 
3.4 Discussion  
A barrier to EMR data abstraction is the development of tools to automate the data 
extraction and the creation of a common data dictionary to pool data across multiple sites.  As 
part of KUMC’s participation in the Patient Centered Outcomes Research Institute (PCORI) 
sponsored Greater Plains Collaborative, a consortium of nine academic centers across the 
Midwest, we had access to HERON, a data abstraction tool using i2b2 technology.  This enabled 
us easily to extract patient data from the KUMC EMR, which has fields vital for measuring 
disease progression and survival in ALS. The KUMC ALS clinic routinely has been collecting 
the ALSFRS and FVC to track progression and manage care in the clinic. We demonstrated the 
feasibility of: (1) electronically extracting this data from KUMC’s EMR, and (2) successfully 
using this data to create models of KUMC patient progression and survival.  
As a positive control for the approach, our survival analyses corroborate previously found 
survival results.  Our models showed strong evidence that the number of years from ALS onset 
to first clinical visit, age, and first recorded ALSFRS score are associated with survival 
(significant in all considered survival models). There was supporting evidence that site of disease 
onset, baseline FVC, and baseline BMI also are associated with survival (significant in one of the 
two considered survival models). All explanatory variables had the expected beneficial or 
detrimental effect on survival (18-25). We were able to extract several key survival variables 
from the EMR and confirm that they were significant while modelling survival. 
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As more clinics use their EMR systems to capture important measures accurately for 
ALS, such as the ALSFRS, it will become possible to leverage large, complete, EMR-based, 
ALS datasets. These datasets will create opportunities to design new varieties of trials and hasten 
ALS treatment discovery. One simple improvement to ALS trials would come from using EMR 
data to augment trial data, as either a placebo arm or as historical controls. In order for this to be 
feasible, we need a better understanding of the variability and progression of patients in the clinic 
setting. Despite seeing the same clinical predictors of survival as other studies, we found ALS 
data derived from the clinic were different in both progression and survival when compared to 
participants recruited for clinical trials as represented by PRO-ACT. Our statistical models 
revealed that the subjects in PRO-ACT had faster disease progressions than KUMC patients. 
Even  though KUMC patients were more likely to be older and have bulbar onset (commonly 
associated with shorter survival time (13, 20, 23, 25)), KUMC patients still had improved 
survival versus PRO-ACT subjects, even after adjusting for significant survival predictors.  
This raises a flag of caution; these preliminary results suggest that the rich source of 
patient data from the EMR may not correspond to what we have been seeing in ALS trials, even 
after adjusting for baseline differences between the clinic and PRO-ACT. Before using this 
approach larger data sets for modeling progression and survival in the clinic setting may be 
required. It also raises the question, how generalizable are the results of ALS trials to the general 
population?  
One major reason for the differences between these two datasets are the trial 
inclusion/exclusion criteria. In most of the PRO-ACT trials, these criteria were designed to select 
patients early in the disease process (symptom onset within 2-3 years of study entry, baseline 
FVC > 60-75% predicted), with the hope of increasing the likelihood for patients to survive to 
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the end of the trial. Recent advances in our understanding of ALS progression has revealed this 
likely is due to  the  heterogeneous patient group selected by inclusion/exclusion criteria  that 
includes both slow and rapid progressing patients (28).   
A simple solution would be to modify the inclusion/exclusion criteria of trials to be more 
representative of the general population; however, the resulting increased patient variability 
would require larger studies. Yet this is readily solvable: with a more general trial population, we 
would be free to use the EMR to augment greatly the control population for these trials. 
Networks such as the Greater Plains Collaborative could provide placebo or standard-of-care 
arms in a variety of designs that could make such large-scale studies possible.  
In our analysis, riluzole use was associated with decreased survival. However, the 
datasets in this paper do not represent a true unbiased population, as patients were not 
randomized to riluzole.  Patients included here self-selected for riluzole use.  As a result, this 
association most likely was due to confounding or some unknown bias; perhaps only the very 
sick or rapidly deteriorating person decided to take riluzole.  
A limitation to this study is that the KUMC data comes from one ALS clinic. Follow up 
would require validation of the approach in a multi-center cohort.  However, this study serves as 
proof of principle that data automatically abstracted from the EMR can be used for modeling 
disease progression and survival in ALS. An additional limitation is data missing from the EMR.  
In order to use EMR-collected data for more sophisticated analysis, clinicians and clinic staff 
will need to ensure complete data entry that includes concomitant medications, participation in 
clinical trials, vital statistics, and agreement on a common minimal ALS data set. For example, 
information on patients’ usage of PEG tubes may be of interest, but was not captured in the 
EMR.  
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In the future, data abstracted from the EMR may fill multiple roles in ALS research, 
including using computable phenotypes for study screening (3), modeling the effect of 
repurposed drugs and supplements, the effects of drugs taken for other medical conditions on 
progression or survival, and running pragmatic studies to determine the best symptomatic 
treatments or timing of interventions (BIPAP, PEG) on clinical outcomes (4). EMR data could 
also be used as a concurrent standard of care control arm, and could be useful in creating large-
sample predictive models (29).  This study serves as proof of concept for the approach of using 
automatically abstracted data from the EMR to model progression and survival. 
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Summary and Future Directions 
Predicting disease progression for patients with ALS could be useful for patients, doctors, 
and clinical trial investigators. Patients could self-track and compare their progression rates to 
those predicted in order to assess the effectiveness of self-administered therapeutics. Doctors 
could use predictions to help their patients to assess how their disease will progress and patients 
plan their future actions accordingly. Clinical trial investigators could benefit immensely from 
predictive models as well. These models could be used in adaptive designs to make better-
informed decisions on randomization schemes and early stopping rules. They could also serve as 
mechanisms for performing imputation.  
Two challenges when predicting ALS disease progression are (1): the sparsity of data, 
which is due to the rareness of ALS, and (2): the heterogeneity of progression rates among 
patients. Because the disease tends to decline in a linear fashion, linear models are appropriate 
for modelling ALS progression. Linear models enjoy a plethora of advantages over other models 
with respect to interpretability, but suffer from large prediction variance when a subject has few 
observed data points. We sought to improve this prediction variance by exploiting knowledge of 
when a patient first began having ALS symptoms. We could use this knowledge to create an 
additional data point (an anchor) that could then be used to reduce the variability of the linear 
predictions.  
We demonstrated that an anchor could be used theoretically, or in practice, when 
modeling several ALS patients’ disease progressions under a standard OLS framework (chapter 
one). We also considered more complex models, such as the Bayes hierarchical linear model, 
and found that using an anchor resulted in improvements with respect to model prediction 
(chapter two). We sought to build the best predictive model for ALS disease progression that we 
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could: this entailed analyzing various potential covariates for improvements to prediction, and 
rigorously testing these models via repeated cross-validation. Finally, we demonstrated that these 
models could be used for both ALS data from the University of Kansas Medical Center’s ALS 
clinic (automatically extracted via the EMR), as well as from the PRO-ACT database of ALS 
clinical trials (chapter three). 
Future works include the comparison of our model to more recently popularized ALS 
predictive models that utilize random forest approaches. We ultimately would like to expand the 
work in chapter three to multiple clinics (rather than solely the clinic at KUMC), so as to get a 
more representative sample of the general ALS population. Finally, one of the key purposes to 
developing ALS predictive models is to use them to design efficient clinical trials which could 
hasten the development of new ALS therapeutics. Therefore it would be prudent to develop the 
framework for a Bayesian adaptive clinical trial that would incorporate these predictive models 
to test new ALS treatments. This framework then could be compared to frequentist designs via 
simulation, incorporating historical ALS data to demonstrate the advantage of using predictive 
models in ALS trial design. It would be our hope that this design could be used in the future to 
assist in developing of new ALS therapeutics. 
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Appendix 
Appendix A1: Full model description 
Let 𝑋𝑖 be a covariate and 𝐴𝐿𝑆𝐹𝑅𝑆𝑖(𝑡) the ALSFRS score for subject 𝑖 at time 𝑡. In this, 𝜎
2 is the 
precision parameter of the non-standardized 𝑇 distribution (3 degrees of freedom), which is 
defined as the inverse of the variance. The linear and onset-anchored hierarchical models are 
then defined as follows: 
𝐴𝐿𝑆𝐹𝑅𝑆𝑖(𝑡)~𝑇3(𝑏0𝑖 + 𝑏1𝑖𝑡, 𝜎
2); 𝐴𝐿𝑆𝐹𝑅𝑆𝑖(𝑡) ∈ [0,40] 
             𝑏0𝑖~𝑁(𝑝00 + 𝑝01𝑋𝑖, 𝜎0
2); 𝑏0𝑖 ∈ [0,40] 
             𝑏1𝑖~𝑁(𝑝10 + 𝑝11𝑋𝑖, 𝜎1
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Appendix A2: BUGS code (R2 OpenBUGS format)  
for (i in 1:N) #N is number of subjects. 
      { 
        for (j in 1:J[i]) #J is a vector containing the number of entries for each subject.  
        { 
          ALSmu[Jtot[i]+j] <-b0[i]+b1[i]*delta[Jtot[i]+j]   
          ALS[Jtot[i]+j] ~ dt(ALSmu[Jtot[i]+j], err, 3)%_%I(0,40) 
           
        } 
        b1_mean[i] <- p10 + p11*covariate[Jtot[i]+1]  
        b0_mean[i] <- p00 + p01*covariate[Jtot[i]+1]  
         
        b1[i]~dnorm(b1_mean[i],err1) %_%I(,0) 
        b0[i]~dnorm(b0_mean[i],err0) %_%I(0,40) 
         
        #predictive draws 
        predmu[i] <-b0[i]+b1[i]*365 
        pred365[i] ~ dt(predmu[i], err, 3) %_%I(0,40) 
         
      } 
       
##priors 
      p00 ~ dnorm(33, 0.111) 
      p01 ~ dnorm(0, 0.00001) 
      p10 ~ dnorm(-0.025, 11) 
      p11 ~ dnorm(0, 0.00001) 
       
      err~dgamma(0.001, 0.001) 
      err1~dgamma(0.001, 0.001) 
      err0~dgamma(0.001, 0.001) 
 
Appendix A3: Full table the effects of covariates on prediction under the onset anchored 
model 
Covariate Name 
Median % MSE reduction 
(negative values signify an 
increase to the MSE) 





values result in 
larger DIC) 
Onset Time 0.0174 0.027 2.8 
FVC: Subject Liters (slope) 0.0095 0.02 -3.5 
Q1: Speech (slope) 0.0081 0.0187 0.8 
Diagnosis Time 0.0059 0.0183 -2.1 
Q7: Turning in Bed(slope) 0.0052 0.0182 -3.5 
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Q8: Walking (slope) 0.0052 0.0254 -2.2 
AST (slope) 0.0043 0.0179 -0.3 
Q5: Cutting (slope) 0.0043 0.0202 -1.5 
Q6: Dressing/Hygiene (slope) 0.0039 0.0223 -1.9 
ALT (slope) 0.0034 0.0166 0.1 
Q2: Salivation (slope) 0.0032 0.0195 1.7 
Q9: Climbing Stairs (slope) 0.003 0.0232 -2 
AST (intercept) 0.0028 0.0162 0.8 
FVC: Percent Normal (slope) 0.0025 0.0225 -3.4 
Race 0.0021 0.0156 -0.1 
ALT (intercept) 0.0021 0.0182 -0.7 
Bilirubin Total (slope) 0.0019 0.0196 -0.5 
Respiratory Rate (intercept) 0.0017 0.0146 0.3 
Q2: Salivation (intercept) 0.0013 0.0203 -1.4 
Creatinine (intercept) 0.0011 0.0152 -0.7 
Age 0.001 0.0185 -2.1 
Q1: Speech (intercept) 0.001 0.0224 2.2 
Potassium (slope) 0.001 0.0136 -0.9 
Onset Site: Bulbar 0.001 0.0171 -0.5 
Height 0.0009 0.0169 0.8 
Weight (slope) 0.0009 0.0174 -1.7 
Sodium (intercept) 0.0008 0.0188 1 
Bilirubin Total (intercept) 0.0008 0.0183 0.8 
Sex 0.0006 0.0169 -0.4 
Q10: Respiratory (slope) 0.0006 0.0153 0.8 
Q4: Handwriting (slope) 0.0006 0.0206 -0.7 
Weight (intercept) 0.0006 0.0181 -0.5 
Q5: Cutting (intercept) 0.0002 0.0224 -4.1 
Q3: Swallowing (slope) -0.0003 0.0214 -0.3 
Q10: Respiratory (intercept) -0.0005 0.0189 -0.4 
Albumin (slope) -0.0006 0.0183 0.2 
Albumin (intercept) -0.0006 0.0184 -0.6 
Creatinine (slope) -0.0007 0.0192 1 
Chloride (slope) -0.0008 0.0201 -0.9 
Used Riluzole -0.0009 0.0196 -0.6 
FVC: Percent Normal (intercept) -0.0012 0.0177 -0.3 
Blood Urea Nitrogen (intercept) -0.0012 0.017 -1.5 
Potassium (intercept) -0.0012 0.015 0.6 
Q3: Swallowing (intercept) -0.0015 0.016 -0.5 
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FVC: Subject Raw Liters (intercept) -0.0016 0.0216 -1.9 
Sodium (slope) -0.0018 0.0187 -0.2 
Chloride (intercept) -0.0021 0.0188 0.2 
BloodUrea Nitrogen (slope) -0.0022 0.02 -1.2 
Respiratory Rate (slope) -0.0027 0.0174 -1.4 
Q7: Turning in Bed (intercept) -0.0039 0.029 -5.9 
Q4: Handwriting (intercept) -0.0043 0.0209 -4.2 
Q6: Dressing/Hygiene (intercept) -0.005 0.0238 -7.8 
Q8: Walking (intercept) -0.0123 0.0226 -1.7 
Q9: Climbing Stairs (intercept) -0.0139 0.0232 -2.8 
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Appendix B1: My Experience at the KUMC ALS Clinic 
 While researching ALS at KUMC, I had the opportunity to visit the KUMC ALS clinic 
and meet actual patients who suffered from the disease. A commonly known struggle with 
studying ALS is the heterogeneity of the disease, and this was very apparent through the data. 
However, I truly experienced the between-subject variability first hand while visiting the clinic. 
Of the three different patients I met, each of them had drastically different manifestations of ALS 
symptoms.  
The first, a middle-aged woman with an incredible optimism, couldn’t move her legs and 
was bound to a wheelchair. Her left arm was beginning to show weakness as well. The next, an 
elderly man, had complete control of his limbs, but was unable to speak or control his mouth, 
resulting in a constant trickle of drool coming from his mouth. The man spoke by writing on a 
notepad he kept with him. The final patient I met had not had the disease for long, and still had 
complete control of her limbs and head; however she had a pervasive muscle weakness 
throughout her body that was worsening over time. 
From my research that ultimately came down to working with spreadsheets and electronic 
data, I knew that ALS was a devastating disease. Seeing it in firsthand in these people, many of 
whom came with their spouses, family members, or children, was tragic. Yet, the amount of 
positivity and hope displayed by the patients was overwhelming. They were excited and 
interested in my research, and were very much intrigued by the idea of being able to predict how 
their disease would progress over the next year. Knowing that my work may be able to improve 
the lives of these patients, in even a small way, gave me a tremendous amount of motivation. 
Truly, it is imperative that as biostatisticians that we remember that the trials we design and 
analyze are: (1) being performed on real people, with all the complexities that entails, (2) have 
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the potential to benefit thousands, if not millions, and (3) give patients hope; hope of a new 
treatment, hope of a cure, or hope of an improved quality of life. Keeping all of this in mind, 
while not getting lost in the numbers and calculations, can be difficult, but remembering these 
facts is of paramount importance. My visit to the ALS clinic was a great reminder of that. 
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Appendix B2: ALSFRS and ALSFRS-R Questionnaire 
The response to each question, from top to bottom, is worth four, three, two, one, or zero 
points. The ALSFRS is found by summing the scores from items one through ten. The ALSFRS-
R is found by summing the scores from items one through twelve.  
1. Speech 
 4: Normal speech processes 
 3: Detectable speech disturbance 
 2: Intelligible with repeating 
 1: Speech combined with nonvocal communication 
 0: Loss of useful speech 
2. Salivation 
 4: Normal 
 3: Slight but definite excess of saliva in mouth; may have nighttime drooling 
 2: Moderately excessive saliva; may have minimal drooling 
 1: Marked excess of saliva with some drooling 
 0: Marked drooling; requires constant tissue or handkerchief 
3. Swallowing 
 4: Normal eating habits 
 3: Early eating problems-occasional choking 
 2: Dietary consistency changes 
 1: Needs supplemental tube feeding 
 0: NPO (exclusively parenteral or enteral feeding) 
4. Handwriting 
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 4: Normal 
 3: Slow or sloppy; all words are legible 
 2: Not all words are legible 
 1: Able to grip pen but unable to write 
 0: Unable to grip pen 
5. Cutting food with gastrostomy 
 4: Normal 
 3: Somewhat slow and clumsy, but no help needed 
 2: Can cut most foods, although clumsy and slow; some help needed 
 1: Food must be cut by someone, but can still feed slowly 
 0: Needs to be fed 
6. Dressing and hygiene 
 4: Normal function 
 3: Independent and complete self-care with effort or decreased efficiency 
 2: Intermittent assistance or substitute methods 
 1: Needs attendant for self-care 
 0: Total dependence 
7. Turning in bed 
 4: Normal 
 3: Somewhat slow and clumsy, but no help needed 
 2: Can turn alone or adjust sheets, but with great difficulty 
 1: Can initiate, but not turn or adjust sheets alone 
 0: Helpless 
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8. Walking 
 4: Normal 
 3: Early ambulation difficulties 
 2: Walks with assistance 
 1: Non-ambulatory functional movement only 
 0: No purposeful leg movement 
9. Climbing stairs 
 4: Normal 
 3: Slow 
 2: Mild unsteadiness or fatigue 
 1: Needs assistance 
 0: Cannot do 
10. Dyspnea 
 4: None 
 3: Occurs when walking 
 2: Occurs with one or more of the following: eating, bathing, dressing (ADL) 
 1: Occurs at rest, difficulty breathing when either sitting or lying 
 0: Significant difficulty, considering using mechanical respiratory support 
11. Orthopnea 
 4: None 
 3: Some difficulty sleeping at night due to shortness of breath. Does not routinely use 
more than two pillows 
 2: Needs extra pillow in order to sleep (more than two) 
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 1: Can only sleep sitting up 
 0: Unable to sleep 
12. Respiratory insufficiency 
 4: None 
 3: Intermittent use of BiPAP 
 2: Continuous use of BiPAP 
 1: Continuous use of BiPAP during the night and day 
 0: Invasive mechanical ventilation by intubation or tracheostomy 
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